ArticleJAMA dermatology2018
Use and Cost of Actinic Keratosis Destruction in the Medicare Part B Fee-for-Service Population, 2007 to 2015.
Article in JAMA dermatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Spontaneous regression rates of actinic keratosis: a systematic review and pooled analysis of randomized controlled trials.Scientific reports · 2022Pooled it
- Randomized controlled trial of fractionated laser resurfacing on aged skin as prophylaxis against actinic neoplasia.The Journal of clinical investigation · 2021Trial
- Opportunities to Avoid Invasive Cancer by Diagnosis and Interception of Preneoplastic Lesions and Cancer Risk Conditions.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Article
- Evaluation of Actinic Keratosis as a Risk Factor for Subsequent Nonskin Cancer Risk.JID innovations : skin science from molecules to population health · 2025Article
- A Non-randomized, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of 10% Aminolevulinic Acid Gel in the Expanded Field-directed Treatment of Actinic Keratosis on the Face and Scalp with Red Light Photodynamic Therapy.The Journal of clinical and aesthetic dermatology · 2025Article
- Developing a questionnaire for assessing clinician- and patient-reported outcomes in actinic keratosis: Results from an expert panel.JAAD international · 2024Article
- Repeated Encounters for Actinic Keratoses in Medicare Patients: A Retrospective Cohort Study.The Journal of investigative dermatology · 2023Article
- Looking into the Skin in Health and Disease: From Microscopy Imaging Techniques to Molecular Analysis.International journal of molecular sciences · 2023Article
- Commentary: Complete Clearance of Actinic Keratosis with Tirbanibulin Ointment 1% is not Correlated with the Severity of Local Skin Reactions.The Journal of clinical and aesthetic dermatology · 2022Article
- Validation of actinic keratosis diagnosis and treatment codes among veterans living with HIV.Pharmacoepidemiology and drug safety · 2022Article
- Approaches to Field Therapy for Actinic Keratoses: Relating Clinical Trial Results to Real-world Practice-A Commentary.The Journal of clinical and aesthetic dermatology · 2022Article
- High-Volume Billing and Reimbursement Trends for Endoscopic Swallowing Studies in the Medicare Population.Dysphagia · 2021Article
- The validity of diagnostic and treatment codes for actinic keratosis in electronic health records.The British journal of dermatology · 2020Article
- Environmental effects of stratospheric ozone depletion, UV radiation and interactions with climate change: UNEP Environmental Effects Assessment Panel, update 2019.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2020Review
- Prevention versus early detection for long-term control of melanoma and keratinocyte carcinomas: a cost-effectiveness modelling study.BMJ open · 2020Article
- Single Ablative Fractional Resurfacing Laser Treatment For Forearm Actinic Keratoses: 6-Month Follow-Up Data From An Intrapatient Comparison Between Treated and Untreated Sites.Lasers in surgery and medicine · 2020Article
- Updates on Treatment Approaches for Cutaneous Field Cancerization.Current dermatology reports · 2019Article
- Trends in Patch Testing in the Medicare Part B Fee-for-Service Population.Dermatitis : contact, atopic, occupational, drugArticle
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
Abstract
Importance: Actinic keratosis is prevalent and has the potential to progress to keratinocyte carcinoma. Changes in the use and costs of actinic keratosis treatment are not well understood in the aging population. Objective: To evaluate trends in the use and costs of actinic keratosis destruction in Medicare patients. Design, Setting, and Participants: A billing claims analysis was performed of the Medicare Part B Physician/Supplier Procedure Summary Master Files and National Summary Data of premalignant skin lesion destructions performed from 2007 to 2015 among Medicare Part B fee-for-service beneficiaries. Main Outcomes and Measures: Mean number of actinic keratosis lesions destroyed and associated treatment payments in 2015 US dollars estimated per 1000 Medicare Part B fee-for-service beneficiaries. Data analysis was performed from November 2017 to July 2018. Results: More than 35.6 million actinic keratosis lesions were treated in 2015, increasing from 29.7 million in 2007. Treated actinic keratosis lesions per 1000 beneficiaries increased from 917 in 2007 to 1051 in 2015, while mean inflation-adjusted payments per 1000 patients decreased from $11 749 to $10 942 owing to reimbursement cuts. The proportion of actinic keratosis lesions treated by independently billing nurse practitioners and physician assistants increased from 4.0% in 2007 to 13.5% in 2015. Conclusions and Relevance: This study's findings suggest that actinic keratosis imposes continuously increasing levels of treatment burden in the Medicare fee-for-service population. Reimbursement decreases have been used to control rising costs of actinic keratosis treatment. Critical research may be warranted to optimize access to actinic keratosis treatment and value for prevention of keratinocyte carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.